Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dicyclohexylcarbodiimide SCHEMBL177067 | 0.86 | EPHX1 (0.71) | EPHX1HIF1AALDH1A1CYP1A2 | |
| Dicyclohexylcarbodiimide SCHEMBL5967555 | 0.86 | EPHX1 (0.71) | EPHX1HIF1AALDH1A1CYP1A2 | |
| SCHEMBL21986399 | 0.84 | EPHX1 (1.00) | EPHX1HIF1AALDH1A1CYP1A2 | |
| SCHEMBL11842065 | 0.84 | EPHX1 (1.00) | EPHX1HIF1AALDH1A1CYP1A2 | |
| Dicyclohexylcarbodiimide SCHEMBL303 | 0.84 | EPHX1 (1.00) | EPHX1HIF1AALDH1A1CYP1A2 | |
| SCHEMBL15667923 | 0.84 | EPHX1 (1.00) | EPHX1HIF1AALDH1A1CYP1A2 | |
| Dicyclohexylcarbodiimide SCHEMBL3173433 | 0.84 | EPHX1 (1.00) | EPHX1HIF1AALDH1A1CYP1A2 | |
| Dicyclohexylcarbodiimide SCHEMBL28613031 | 0.82 | EPHX1 (0.83) | EPHX1HIF1AALDH1A1CYP1A2 | |
| Dicyclohexylcarbodiimide SCHEMBL28399447 | 0.82 | EPHX1 (0.94) | EPHX1HIF1AALDH1A1CYP1A2 | |
| Dicyclohexylcarbodiimide SCHEMBL22804053 | 0.82 | EPHX1 (0.94) | EPHX1HIF1AALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9522899-B2 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof | NANJIAN CAVENDISH BIO-ENGINEERING TECHNOLOGY CO., LTD (CN) | 2016-12-20 | — | — | US | disclosed |
| US-20150284359-A1 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2015-10-08 | — | — | US | disclosed |
| US-20150284329-A1 | Methods for synthesizing 3-(Substituted Dihydroisoindolinone-2-YI)-2, 6-Dioxopiperidine, and intermediates thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2015-10-08 | — | — | US | disclosed |
| US-9085530-B2 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2015-07-21 | — | — | US | disclosed |
| EP-2438053-B1 | METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF | NANJING CAVENDISH BIO ENGINEERING TECHNOLOGY CO LTD (CN) | 2013-09-11 | — | — | EP | disclosed |
| EP-2438053-A1 | METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2012-04-11 | — | — | EP | disclosed |
| US-20120077982-A1 | Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2012-03-29 | — | — | US | disclosed |
| WO-2010139266-A1 | METHODS FOR SYNTHESIZING 3-(SUBSTITUTED DIHYDROISOINDOLINONE-2-YL)-2,6-DIOXOPIPERIDINE, AND INTERMEDIATES THEREOF | Nanjing Cavendish Bio-Engineering Technology Co., Ltd. (CN) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150284329-A1 | Methods for synthesizing 3-(Substituted Dihydroisoindolinone-2-YI)-2, 6-Dioxopiperidine, and intermediates thereof | DHPS, QDPR, FDPS | EPHX1 361/4885HIF1A 2342/4885ALDH1A1 279/4885 |
| US-20120077982-A1 | Methods for Synthesizing 3-(Substituted Dihydroisoindolinone-2-YL)-2, 6-Dioxopiperidine, and Intermediates Thereof | DHPS, QDPR, FDPS | EPHX1 321/4885HIF1A 2581/4885ALDH1A1 168/4885 |
| US-20150284359-A1 | Methods for synthesizing 3-(substituted dihydroisoindolinone-2-yl)-2, 6-dioxopiperidine, and intermediates thereof | DHPS, QDPR, FDPS | EPHX1 321/4885HIF1A 2581/4885ALDH1A1 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.